{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:42:22Z","timestamp":1791333742185,"version":"4.3.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003187","name":"NSF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AI165077"],"award-info":[{"award-number":["P01AI165077"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI151797"],"award-info":[{"award-number":["AI151797"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["JP19fk0108113"],"award-info":[{"award-number":["JP19fk0108113"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["DGE-2039655"],"award-info":[{"award-number":["DGE-2039655"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006778","name":"Georgia Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007015","name":"University of Wisconsin-Madison","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ebiom.2022.104341","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T19:17:46Z","timestamp":1668194266000},"page":"104341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses"],"prefix":"10.1016","volume":"86","author":[{"given":"Peter J.","family":"Halfmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Maemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Armbrust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie E.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan J.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-4098","authenticated-orcid":false,"given":"Ravi S.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104341_bib1","series-title":"WHO COVID-19 Dashoard","year":"2020"},{"issue":"7830","key":"10.1016\/j.ebiom.2022.104341_bib2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"issue":"10269","key":"10.1016\/j.ebiom.2022.104341_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.ebiom.2022.104341_bib4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104341_bib5","series-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19","author":"Sadoff","year":"2021"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104341_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104341_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104341_bib8","article-title":"Immunogenic superiority and safety of Biological E's CORBEVAX\u2122 vaccine compared to COVISHIELD\u2122 (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial","author":"Thuluva","year":"2022","journal-title":"medRxiv"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104341_bib9","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.ebiom.2022.104341_bib10","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7857","key":"10.1016\/j.ebiom.2022.104341_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104341_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.ebiom.2022.104341_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104341_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-022-00672-4","article-title":"Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins","volume":"32","author":"Xu","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.ebiom.2022.104341_bib15","article-title":"Omicron sub-lineages BA.4\/BA.5 escape BA.1 infection elicited neutralizing immunity","author":"Khan","year":"2022","journal-title":"medRxiv"},{"issue":"12","key":"10.1016\/j.ebiom.2022.104341_bib16","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/nm.3985","article-title":"A\u00a0SARS-like cluster of circulating bat coronaviruses shows potential for human emergence","volume":"21","author":"Menachery","year":"2015","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104341_bib17","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1073\/pnas.1517719113","article-title":"SARS-like WIV1-CoV poised for human emergence","volume":"113","author":"Menachery","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104341_bib18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"7592","key":"10.1016\/j.ebiom.2022.104341_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature16988","article-title":"Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer","volume":"531","author":"Walls","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104341_bib20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/s41590-022-01222-1","article-title":"Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses","volume":"23","author":"He","year":"2022","journal-title":"Nat Immunol"},{"issue":"6504","key":"10.1016\/j.ebiom.2022.104341_bib21","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A\u00a0neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104341_bib22","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1038\/s41467-021-23074-3","article-title":"Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection","volume":"12","author":"Song","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104341_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109353","article-title":"Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects","volume":"36","author":"Jennewein","year":"2021","journal-title":"Cell Rep"},{"issue":"6559","key":"10.1016\/j.ebiom.2022.104341_bib24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix-specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"issue":"637","key":"10.1016\/j.ebiom.2022.104341_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi9215","article-title":"A\u00a0human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection","volume":"14","author":"Zhou","year":"2022","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104341_bib26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41423-022-00847-4","article-title":"A\u00a0spike protein S2 antibody efficiently neutralizes the Omicron variant","volume":"19","author":"Hu","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.ebiom.2022.104341_bib27","article-title":"Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease","author":"Zhou","year":"2022","journal-title":"bioRxiv"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104341_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110210","article-title":"Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern","volume":"38","author":"Li","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.ebiom.2022.104341_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100313","article-title":"Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions","author":"Shiakolas","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104341_bib30","article-title":"Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses","volume":"2","author":"Ladner","year":"2021","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104341_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01991-20","article-title":"Protein-reactive IgG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit","volume":"11","author":"Nguyen-Contant","year":"2020","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104341_bib32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41467-021-21968-w","article-title":"A\u00a0conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104341_bib33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41594-021-00596-4","article-title":"Structural basis for broad coronavirus neutralization","volume":"28","author":"Sauer","year":"2021","journal-title":"Nat Struct Mol Biol"},{"issue":"550","key":"10.1016\/j.ebiom.2022.104341_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3539","article-title":"Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits","volume":"12","author":"Ravichandran","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2022.104341_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.immunol.15.1.235","article-title":"Neutralizing antiviral B cell responses","volume":"15","author":"Bachmann","year":"1997","journal-title":"Annu Rev Immunol"},{"issue":"6510","key":"10.1016\/j.ebiom.2022.104341_bib36","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1126\/science.abd0826","article-title":"Structure-based design of prefusion-stabilized SARS-CoV-2 spikes","volume":"369","author":"Hsieh","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104341_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s42003-021-02128-8","article-title":"Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization","volume":"4","author":"Chiba","year":"2021","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104341_bib38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jmb.2013.09.016","article-title":"Plug-and-play pairing via defined divalent streptavidins","volume":"426","author":"Fairhead","year":"2014","journal-title":"J\u00a0Mol Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104341_bib39","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nprot.2008.20","article-title":"Imaging proteins in live mammalian cells with biotin ligase and monovalent streptavidin","volume":"3","author":"Howarth","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.ebiom.2022.104341_bib40","article-title":"Visualizing proteins and macromolecular complexes by negative stain EM: from grid preparation to image acquisition","volume":"58","author":"Booth","year":"2011","journal-title":"J\u00a0Vis Exp"},{"key":"10.1016\/j.ebiom.2022.104341_bib41","article-title":"Sample preparation and imaging of exosomes by transmission electron microscopy","volume":"131","author":"Jung","year":"2018","journal-title":"J\u00a0Vis Exp"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104341_bib42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jsb.2005.07.007","article-title":"Automated electron microscope tomography using robust prediction of specimen movements","volume":"152","author":"Mastronarde","year":"2005","journal-title":"J\u00a0Struct Biol"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104341_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nmeth.4193","article-title":"MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy","volume":"14","author":"Zheng","year":"2017","journal-title":"Nat Methods"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104341_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jsb.2015.04.016","article-title":"Single particle tomography in EMAN2","volume":"190","author":"Galaz-Montoya","year":"2015","journal-title":"J\u00a0Struct Biol"},{"issue":"28","key":"10.1016\/j.ebiom.2022.104341_bib45","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104341_bib46","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","article-title":"A\u00a0mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104341_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002140","article-title":"Refocusing the immune response to selected epitopes on a Zika virus protein antigen by nanopatterning","author":"Castro","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.ebiom.2022.104341_bib49","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"6498","key":"10.1016\/j.ebiom.2022.104341_bib50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/371623a0","article-title":"Crystal structure of an RNA bacteriophage coat protein-operator complex","volume":"371","author":"Valegard","year":"1994","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104341_bib51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jmb.2008.04.049","article-title":"Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2","volume":"380","author":"Peabody","year":"2008","journal-title":"J\u00a0Mol Biol"},{"issue":"7798","key":"10.1016\/j.ebiom.2022.104341_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A\u00a0new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104341_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110394","article-title":"Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model","volume":"38","author":"Halfmann","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.ebiom.2022.104341_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front Immunol"},{"issue":"7862","key":"10.1016\/j.ebiom.2022.104341_bib55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104341_bib56","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1586\/erv.11.18","article-title":"Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer","volume":"10","author":"Ragupathi","year":"2011","journal-title":"Expet Rev Vaccine"},{"issue":"45","key":"10.1016\/j.ebiom.2022.104341_bib57","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1016\/j.vaccine.2010.08.098","article-title":"Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and \u03b1DEC-CSP in non human primates","volume":"28","author":"Tewari","year":"2010","journal-title":"Vaccine"},{"issue":"655","key":"10.1016\/j.ebiom.2022.104341_bib58","doi-asserted-by":"crossref","first-page":"eabn3715","DOI":"10.1126\/scitranslmed.abn3715","article-title":"SARS-CoV-2 S2\u2013targeted\u00a0vaccination elicits broadly neutralizing antibodies","volume":"14","author":"Ng","year":"2022","journal-title":"Sci Transl Med"},{"issue":"6530","key":"10.1016\/j.ebiom.2022.104341_bib59","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abf6840","article-title":"Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice","volume":"371","author":"Cohen","year":"2021","journal-title":"Science"},{"issue":"6606","key":"10.1016\/j.ebiom.2022.104341_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq0839","article-title":"Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models","volume":"377","author":"Cohen","year":"2022","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.ebiom.2022.104341_bib61","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","article-title":"Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines","volume":"184","author":"Walls","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104341_bib62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in\u00a0vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.104341_bib63","first-page":"51","article-title":"Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a randomised, placebo-controlled, observer-blinded phase 1\/2 trial","author":"Song","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ebiom.2022.104341_bib64","series-title":"SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine with ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults","year":"2022"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:35:50Z","timestamp":1778873750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422005230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":63,"alternative-id":["S2352396422005230"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104341","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104341"}}